Loading…
HUTCHMED (China) Limited is projected to rise to $12.18 by 2027, a +4% move from its current price of $11.72. HCM is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $11.54 | $11.72 | $11.89 | -0.04% |
| May 30 | $11.46 | $11.71 | $11.96 | -0.07% |
| May 31 | $11.41 | $11.71 | $12.02 | -0.11% |
| Jun 1 | $11.36 | $11.70 | $12.06 | -0.14% |
| Jun 2 | $11.31 | $11.70 | $12.10 | -0.18% |
| Jun 3 | $11.27 | $11.69 | $12.13 | -0.22% |
| Jun 4 | $11.23 | $11.69 | $12.17 | -0.25% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $11.23 | $11.69 | $12.17 | -0.25% |
| Week 2 | $11.02 | $11.66 | $12.34 | -0.50% |
| Week 3 | $10.86 | $11.63 | $12.46 | -0.75% |
| Week 4 | $10.71 | $11.60 | $12.57 | -1.00% |
| Week 5 | $10.59 | $11.57 | $12.65 | -1.25% |
| Week 6 | $10.47 | $11.54 | $12.73 | -1.50% |
| Week 7 | $10.36 | $11.52 | $12.80 | -1.75% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML).
In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc.
The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
HUTCHMED (China) Limited trades on the stock market under the symbol HCM. The current price is $11.99 per share and the market capitalization is $2.06B. The stock is ranked 1982 in market position.
The 2026 forecast shows an average price of $11.99 with a high of $15.77 and a ROI of 0, indicating a NEUTRAL stance in that year. Looking further ahead, the forecast turns bullish in 2029 and beyond, with the 2030 average at $17.21 and a ROI of 43.5, and the 2050 average at $63.99 with a ROI of 433.7.
A major floor 22.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 34.3% above — a clean break opens room to run.
A major ceiling 45.7% above — clearing it would confirm fresh momentum.
Key HCM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HCM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $11.88 | Sell | $11.89 | Sell |
| MA 10 | $12.13 | Sell | $12.15 | Sell |
| MA 20 | $12.67 | Sell | $12.64 | Sell |
| MA 50 | $13.85 | Sell | $13.47 | Sell |
| MA 100 | $14.29 | Sell | $13.99 | Sell |
| MA 200 | $14.71 | Sell | $14.52 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 23.81 | Buy |
| Stoch RSI (14) | 15.45 | Buy |
| CCI (20) | -116.83 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.05 | Sell |
| ROC (12) | -10.74 | Sell |
| Bollinger %B (20,2) | 0.11 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.62 | Sell |
| Awesome (5,34) | -1.67 | Sell |
| Ultimate (7,14,28) | 16.97 | Buy |
| Momentum (10) | -0.95 | Sell |
| Aroon Osc (25) | -100.00 | Sell |
| Hull MA (9) | 11.75 | Sell |
| ADX (14) | 39.05 | Sell |
| ATR (14) | 0.18 | Info |
The 30-day technical picture is NEUTRAL. The RSI(14) is 30. The 50-day simple moving average sits at $13.95 and the 200-day simple moving average at $14.75. The stock has a support level at $11.91 and a resistance level at $15.74. Over the past 30 days, the price has ranged from $10.83 to $13.28.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $11.72 | $11.72 | $15.31 | 0% | Neutral | |
| $9.95 | $12.18 | $15.60 | +4% | Neutral | |
| $10.22 | $12.74 | $16.75 | +9% | Neutral | |
| $11.19 | $14.16 | $19.00 | +21% | Bullish | |
| $12.87 | $16.50 | $22.54 | +41% | Bullish | |
| $13.89 | $18.03 | $25.01 | +54% | Bullish | |
| $13.88 | $18.21 | $25.62 | +55% | Bullish | |
| $14.34 | $19.01 | $27.09 | +62% | Bullish | |
| $14.66 | $19.63 | $28.30 | +68% | Bullish | |
| $15.35 | $20.74 | $30.23 | +77% | Bullish | |
| $19.41 | $27.36 | $41.77 | +133% | Bullish | |
| $39.49 | $59.69 | $97.66 | +409% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $11.72 | $11.72 | $13.71 | +0.00% |
| June 2026 | $9.88 | $11.53 | $13.71 | -1.65% |
| July 2026 | $9.67 | $11.34 | $13.61 | -1.61% |
| August 2026 | $9.87 | $11.63 | $14.06 | +2.52% |
| September 2026 | $10.04 | $11.88 | $14.44 | +2.13% |
| October 2026 | $9.96 | $11.83 | $14.46 | -0.42% |
| November 2026 | $10.08 | $12.00 | $14.75 | +1.49% |
| December 2026 | $10.39 | $12.41 | $15.31 | +3.39% |
Click any year to see its month-by-month HCM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The HCM price prediction for 2026 points to an average of $11.72 (low $11.72, high $15.31) — a potential gain of 0% on today's $11.72. A consolidation phase looks the most probable path here.
In 2027, HCM is projected to trade between $9.95 and $15.60, averaging $12.18 — a potential gain of +4% from today's $11.72. That is up +4% on the projected 2026 average. Price action looks broadly range-bound.
HUTCHMED (China) Limited's 2028 outlook centres on $12.74, within a $10.22 to $16.75 range. That is up +5% on the projected 2027 average. That marks a +9% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, HCM could reach as high as $19.00, with a base case around $14.16 and support toward $11.19 — roughly +21% from $11.72. Momentum favours further upside here.
Expect HCM to range from $12.87 to $22.54 through 2030. The $16.50 average target implies a +41% move from current prices. That is up +17% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The HCM price prediction for 2031 points to an average of $18.03 (low $13.89, high $25.01) — a potential gain of +54% on today's $11.72. Momentum favours further upside here.
In 2032, HCM is projected to trade between $13.88 and $25.62, averaging $18.21 — a potential gain of +55% from today's $11.72. That is up +1% on the projected 2031 average. Buyers look set to stay in control over this stretch.
HUTCHMED (China) Limited's 2033 outlook centres on $19.01, within a $14.34 to $27.09 range. That is up +4% on the projected 2032 average. That marks a +62% change versus current levels. Momentum favours further upside here.
By 2034, HCM could reach as high as $28.30, with a base case around $19.63 and support toward $14.66 — roughly +68% from $11.72. Buyers look set to stay in control over this stretch.
Expect HCM to range from $15.35 to $30.23 through 2035. The $20.74 average target implies a +77% move from current prices. That is up +6% on the projected 2034 average. Momentum favours further upside here.
The HCM price prediction for 2040 points to an average of $27.36 (low $19.41, high $41.77) — a potential gain of +133% on today's $11.72. Buyers look set to stay in control over this stretch.
In 2050, HCM is projected to trade between $39.49 and $97.66, averaging $59.69 — a potential gain of +409% from today's $11.72. That is up +118% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in HCM today (≈ 85.324232 HCM) could be worth
$5,092.59
+$4,092.59 (+409%) by 2050 · US Dollar
Based on the average projected HCM price of $59.69 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HCMwould be worth at today's price.
$1,000 invested in HCM on May 27, 2025 (≈ 74.571216 HCM) would be worth
$873.97
-$126.03 (-12.6%) today · 0.87× · US Dollar
Based on a HCM entry price of $13.41 vs. today's $11.72.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $11.91 | $984.05 | -1.6% |
| 1 month ago | $13.45 | $871.38 | -12.9% |
| 3 months ago | $14.72 | $796.2 | -20.4% |
| 6 months ago | $14.42 | $812.76 | -18.7% |
| 1 year ago | $13.41 | $873.97 | -12.6% |
| All time (5.0y) ago | $29.89 | $392.1 | -60.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HCM forecast.
Our base-case forecast reaches $23.00 around 2040.
Implied market cap at $23.00: $3.95B
The multi-year forecast shows a bullish trend beginning in 2029 and continuing through 2050. The 2029 forecast has an average price of $14.86 and a max of $19.94 (ROI 23.9%), while 2030 shows an average of $17.21 (ROI 43.5%). By 2040, the average is projected to be $29.23 with a 143.8% ROI, and by 2050 the average is $63.99 with a 433.7% ROI.
The forecast sentiment is NEUTRAL for 2026–2028 and BULLISH from 2029 onward. These figures are estimates and not guaranteed, and they should be weighed against the inherent uncertainties of market movements.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $17.21 and a ROI of 43.5, with a BULLISH sentiment.
Forecasts indicate a path from NEUTRAL in 2026–2028 to BULLISH from 2029 onward, with the average price rising to $63.99 by 2050 and a max of $104.71 in 2050.
Yes. The max forecast for 2050 is $104.71, with the 2050 average of $63.99 and a ROI of 433.7.
The 2026 forecast lists a min of $11.91, an average of $11.99, a max of $15.77, and a ROI of 0 with NEUTRAL sentiment.
The 2040 forecast shows an average price of $29.23 with a ROI of 143.8 and a BULLISH sentiment.
HUTCHMED (China) Limited Community Discussion
0Share your HUTCHMED (China) Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.